These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 30110398)

  • 1. Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.
    Schweizer MT; Haugk K; McKiernan JS; Gulati R; Cheng HH; Maes JL; Dumpit RF; Nelson PS; Montgomery B; McCune JS; Plymate SR; Yu EY
    PLoS One; 2018; 13(8):e0202709. PubMed ID: 30110398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    Kim SI; Szeto AH; Morgan KP; Brower B; Dunn MW; Khandani AH; Godley PA; Rose TL; Basch EM; Milowsky MI; Whang YE; Crona DJ
    PLoS One; 2021; 16(12):e0262326. PubMed ID: 34972194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction: Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
    Clin Cancer Res; 2017 Jan; 23(1):323. PubMed ID: 28049163
    [No Abstract]   [Full Text] [Related]  

  • 4. Correction: Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer.
    Tinzl M; Chen B; Chen SY; Semenas J; Abrahamsson PA; Dizeyi N
    PLoS One; 2018; 13(12):e0209544. PubMed ID: 30562402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Commentary on: "Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study." Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Hirmand M, Smith MR. Institut de Recherche Clinique, Université Catholique de Louvain, Brussels, Belgium. Electronic address: bertrand.tombal@uclouvain.be. Aarhus University Hospital, Aarhus, Denmark. Herlev Hospital, Herlev, Denmark. AZ Groeninge Kortrijk, Kortrijk, Belgium. UZ Leuven, Leuven, Belgium. Klinik und Poliklinik für Urologie, RWTH University Aachen, Aachen, Germany. Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. UZ Brussel, Brussels, Belgium. Univerzita Karlova v Praze, Prague, Czech Republic. Astellas Pharma Global Development, Leiden, Netherlands. Astellas Pharma Global Development, Northbrook, IL, USA. Medivation Inc, San Francisco, CA, USA. Massachusetts General Hospital Cancer Center, Boston, MA, USA: Lancet Oncol. 2014 May;15(6):592-600; doi: 10.1016/S1470-2045(14)70129-9. [Epub 2014 Apr 14].
    Trump D
    Urol Oncol; 2016 May; 34(5):248-9. PubMed ID: 25937426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer.
    McCool R; Fleetwood K; Glanville J; Arber M; Goodall H; Naidoo S
    Value Health; 2018 Oct; 21(10):1259-1268. PubMed ID: 30314628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction: A genetic variant in SLC28A3, rs56350726, is associated with progression to castration-resistant prostate cancer in a Korean population with metastatic prostate cancer.
    Jo JK; Oh JJ; Kim YT; Moon HS; Choi HY; Park S; Ho JN; Yoon S; Park HY; Byun SS
    Oncotarget; 2018 Aug; 9(61):31938. PubMed ID: 30159135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction: Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort.
    PLOS ONE Staff
    PLoS One; 2017; 12(4):e0175606. PubMed ID: 28384273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction: The Zinc-Schiff Base-Novicidin Complex as a Potential Prostate Cancer Therapy.
    Milosavljevic V; Haddad Y; Merlos Rodrigo MA; Moulick A; Polanska H; Hynek D; Heger Z; Kopel P; Adam V
    PLoS One; 2018; 13(9):e0204441. PubMed ID: 30222782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction: Targeting Hsp27/eIF4E interaction with phenazine compound: a promising alternative for castration-resistant prostate cancer treatment.
    Ziouziou H; Andrieu C; Laurini E; Karaki S; Fermeglia M; Oueslati R; Taieb D; Camplo M; Siri O; Pricl S; Katsogiannou M; Rocchi P
    Oncotarget; 2018 Jun; 9(47):28797. PubMed ID: 29983898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction: Hsa-miRNA-765 as a Key Mediator for Inhibiting Growth, Migration and Invasion in Fulvestrant-Treated Prostate Cancer.
    Leung YK; Chan QK; Ng CF; Ma FM; Tse HM; To KF; Maranchie J; Ho SM; Lau KM
    PLoS One; 2019; 14(3):e0214184. PubMed ID: 30883603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction: KML001 Induces Apoptosis and Autophagic Cell Death in Prostate Cancer Cells via Oxidative Stress Pathway.
    You D; Kim Y; Jang MJ; Lee C; Jeong IG; Cho YM; Hwang JJ; Hong JH; Ahn H; Kim CS
    PLoS One; 2019; 14(11):e0225087. PubMed ID: 31693709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction: MicroRNA-302a Suppresses Tumor Cell Proliferation by Inhibiting AKT in Prostate Cancer.
    PLOS ONE Editors
    PLoS One; 2020; 15(10):e0241462. PubMed ID: 33091075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction: Secretome profiling of PC3/nKR cells, a novel highly migrating prostate cancer subline derived from PC3 cells.
    Jeon JM; Kwon OK; Na AY; Sung EJ; Cho IJ; Kim M; Yea SS; Chun SY; Lee JN; Ha YS; Kwon TG; Lee S
    PLoS One; 2019; 14(9):e0222693. PubMed ID: 31518368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction: Optimal costs of HIV pre-exposure prophylaxis for men who have sex with men.
    McKenney J; Chen A; Hoover KW; Kelly J; Dowdy D; Kasaie P; Sullivan PS; Rosenberg ES
    PLoS One; 2017; 12(7):e0182593. PubMed ID: 28750093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction: Androgen-Sensitized Apoptosis of HPr-1AR Human Prostate Epithelial Cells.
    Chen C; Dienhart JA; Bolton EC
    PLoS One; 2019; 14(3):e0213800. PubMed ID: 30865707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction: The Zinc-Schiff Base-Novicidin Complex as a Potential Prostate Cancer Therapy.
    Milosavljevic V; Haddad Y; Merlos Rodrigo MA; Moulick A; Polanska H; Hynek D; Heger Z; Kopel P; Adam V
    PLoS One; 2022; 17(6):e0270734. PubMed ID: 35749472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction: Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis.
    Operario DJ; Koeppel AF; Turner SD; Bao Y; Pholwat S; Banu S; Foongladda S; Mpagama S; Gratz J; Ogarkov O; Zhadova S; Heysell SK; Houpt ER
    PLoS One; 2017; 12(7):e0181284. PubMed ID: 28686689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction: Population Screening Using Sewage Reveals Pan-Resistant Bacteria in Hospital and Community Samples.
    PLOS ONE Staff
    PLoS One; 2017; 12(1):e0170538. PubMed ID: 28081232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.